Prefrontal cortical and hippocampal modulation of dopamine-mediated effects.
Lipska
B K
BK
Clinical Brain Disorders Branch, National Institute of Mental Health, Washington, D.C. 20032, USA.
Weinberger
D R
DR
D000375:Aging; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001058:Apomorphine / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D006801:Humans; D009043:Motor Activity / Q000187:drug effects; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D051381:Rats; D013216:Reflex, Startle / Q000187:drug effects; D012559:Schizophrenia / Q000503:physiopathology*; D012741:Sexual Maturation; D013239:Stereotyped Behavior / Q000187:drug effects; D013315:Stress, Psychological; D013569:Synapses / Q000502:physiology; D009435:Synaptic Transmission
D000661:Amphetamine; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine